# Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol

> **NCT02669459** · PHASE3 · UNKNOWN · sponsor: **Erasmus Medical Center** · enrollment: 433 (estimated)

## Conditions studied

- Cervical Intraepithelial Neoplasia

## Interventions

- **DRUG:** Imiquimod
- **PROCEDURE:** LLETZ

## Key facts

- **NCT ID:** NCT02669459
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2019-03
- **Final completion:** 2020-03
- **Target enrollment:** 433 (ESTIMATED)
- **Last updated:** 2018-02-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02669459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02669459, "Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02669459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*